Ibogaine Treatment Legality — the article + the world, ranked

A fuller editorial guide to ibogaine treatment legality is coming soon. For now, the ranking below compares every country we have assessed on it — open a country's report for the cited detail behind its score.

The country comparison

Which countries are best for ibogaine treatment legality

The destinations ranked high→low under this lens — each with the reasoning behind its score, the cited evidence one click down, and its full report. The verdict is free; the report is the depth.

19 / 19 Countries ranked

Researched and assessed by the Epidaurus editorial pipeline against our published scale. A country below the rule is not yet assessed enough — never ranked last.

1 Brazil BR 4.0/5 Good Brazil's ibogaine therapy operates in a legal gray area with documented government tolerance. While ibogaine is unscheduled under national controlled substances law (Portaria 344/1998) and lacks ANVISA registration as... Full report
The evidence behind this score 6 cited points
- Ibogaine is unscheduled under Portaria SVS/MS 344/1998, not a controlled substance, giving licensed physicians prescriptive freedom under clinical discretion
- Dr. Rasmussen conducted 2,000+ treatments since 1994 without criminal prosecution; multiple facilities including Bienstar Wellness operate openly across São Paulo, Ourinhos, and Curitiba
- São Paulo's CONED-SP (2016) issued a resolution recommending hospital-based ibogaine treatment with medical, psychiatric, and psychological oversight; CREMESP recognized physician prescription authority
- ANVISA explicitly discourages commercial advertising and prohibits commercial sale under RDC 204/2006, but has not mounted criminal enforcement against hospital-based clinical practitioners
- SENAPRED (federal drug agency) formally opposes ibogaine but has not reported criminal actions against treating physicians; enforcement is selective, targeting only the 2016 underground clinic after a patient fatality
- Foreign patients access treatment via standard tourist visas with no special medical visa requirements or immigration restrictions
Read the full Brazil report →
2 Mexico MX 4.0/5 Good Mexico offers good legal access to ibogaine treatment through a permissive regulatory gray zone with government tolerance. While ibogaine is not explicitly legal, it is unregulated and not prohibited, allowing multipl... Full report
The evidence behind this score 5 cited points
- Ibogaine is unregulated in Mexico, creating a legal gray zone that allows clinics to operate freely without explicit legal prohibition or government enforcement
- Multiple established clinics have operated openly for 15-20 years with demonstrated government tolerance and no documented prosecutions or crackdowns
- COFEPRIS (Mexican health authority) requires facility licensing and inspection for hygiene, medical equipment, and staff qualifications, providing baseline regulatory oversight
- International patients face no special visa requirements, legal restrictions, or specific authorization barriers—US citizens need only passport and Tourist Card for stays under 180 days
- Current operational reality reflects 'tacit acceptance' of ibogaine treatment when administered by qualified medical professionals in licensed clinics, with no enforcement against providers or patients
Read the full Mexico report →
3 Colombia CO 4.0/5 Good Colombia's ibogaine therapy operates in a legal gray area with clear government tolerance. Ibogaine is absent from the country's controlled substance schedules and receives no explicit prohibition, while multiple trea... Full report
The evidence behind this score 4 cited points
- Ibogaine is absent from Colombia's controlled substance schedules (Resolution 315/2020 and Resolution 116/2026) and is not scheduled under any applicable UN convention, meaning no legal prohibition exists against its possession or therapeutic use
- At least 6 treatment centers openly advertise ibogaine therapy with scheduled programs and public pricing, with no documented prosecutions or government interference under the reformist Petro administration (2022-present)
- Foreign nationals from the US, EU, and Canada enter Colombia visa-free for up to 90 days or can obtain a Medical Treatment Visa (Tipo V) for extended stays; no customs restrictions on ibogaine have been documented, and no foreign patients have faced legal prosecution for seeking ibogaine treatment
- The 2023–2033 National Drug Policy Plan explicitly reframes enforcement away from drug-related therapies and toward structural causes of trafficking, creating a policy environment where ibogaine therapy providers face minimal legal risk
Read the full Colombia report →
4 Spain ES 4.0/5 Good Spain's legal gray area status combined with clear government tolerance and active support for ibogaine research creates a favorable environment for medical tourism. Ibogaine is unscheduled, multiple clinics operate o... Full report
The evidence behind this score 5 cited points
- Ibogaine is not listed in Spain's Royal Decree 2829/1977 controlled substance annex or any subsequent AEMPS updates, creating a legal gray area rather than explicit authorization or prohibition
- The Catalan government partially funded a Phase II clinical trial at Hospital Universitari Sant Joan de Reus, demonstrating active institutional support for ibogaine research
- Multiple ibogaine clinics operate openly in Barcelona, Granada, Marbella, Malaga, and Tenerife with zero documented enforcement actions against providers or patients
- International patients can enter Spain on standard Schengen visas without special medical authorization, and ibogaine is not subject to import restrictions
- No formal practitioner licensing or facility certification requirements exist specific to ibogaine, meaning clinic standards and medical rigor vary considerably across operators
Read the full Spain report →
5 Germany DE 3.0/5 Moderate Germany presents a mixed legal status: ibogaine is not criminally scheduled, but is blocked by pharmaceutical law requiring marketing authorization for any medicinal product. While no ibogaine treatment is currently a... Full report
The evidence behind this score 5 cited points
- Ibogaine absent from all three BtMG schedules (Anlage I, II, III) confirming no criminal prohibition
- Medicinal Products Act (AMG) prohibits administering unapproved drugs; up to 3 years' imprisonment possible for commercial provision
- No licensed ibogaine treatment facilities exist in Germany; no documented enforcement actions or prosecutions
- Heilversuch (individual therapeutic trial) provides theoretical legal pathway for experimental treatment under specific conditions
- July 2025 BfArM approval of psilocybin compassionate use program demonstrates institutional openness to psychedelic medicine
Read the full Germany report →
6 United States US 2.5/5 Moderate Ibogaine remains federally illegal (Schedule I) with documented active enforcement, but the U.S. government has officially signaled rapid support for legalization. As of June 2026, medical tourists face absolute feder... Full report
The evidence behind this score 5 cited points
- Schedule I controlled substance classification with federal felony penalties for possession and distribution; September 2025 DEA prosecution resulted in 48-month prison sentence
- April 2026 Executive Order explicitly directs FDA/DEA to establish Right to Try pathways for ibogaine compounds
- Oregon HB 4110 (February 2026) legalizes physician-supervised ibogaine therapy effective January 1, 2027; Colorado Proposition 122 allows supervised healing center access starting June 2026
- Zero licensed treatment centers currently operational in U.S.; foreign nationals face same federal prohibition as domestic patients with no special visa or legal pathway
- Seven states enacted ibogaine research legislation and eight more have active bills; DEA increased production quota 40% to support expanded research
Read the full United States report →
7 Thailand TH 2.0/5 Poor Thailand presents a legal gray area with substantial risk where ibogaine is not scheduled as a narcotic but is explicitly prohibited from importation under the Customs Act without government authorization. While two r... Full report
The evidence behind this score 4 cited points
- Ibogaine is not listed in Thailand's Narcotics Act (5 categories) or Psychotropic Substances Act (4 schedules), but Section 44/2523 B of the Thai Customs Act 1979 explicitly prohibits importation without government permission
- Two retreat centers (IBogaine Thailand since 2014, Root Healing) openly advertise treatment with no documented prosecution under narcotics law; the 2014 Koh Phangan death produced investigation but no narcotics charges
- Foreign patients cannot legally import ibogaine into Thailand and do not qualify for the MT Medical Visa (centers not recognized hospitals); providers source through undisclosed illegal import channels
- Thailand has extremely aggressive drug enforcement (206,080 drug offenders = 74.5% of prison population as of January 2024); December 2024 enforcement action against cannabis shop shows enforcement materializes rapidly after high-profile incidents
Read the full Thailand report →
8 United Kingdom GB 2.0/5 Poor The UK's Psychoactive Substances Act 2016 explicitly criminalizes ibogaine production, supply, import, and export with maximum seven-year sentences, making commercial provision illegal. No licensed ibogaine treatment ... Full report
The evidence behind this score 4 cited points
- Psychoactive Substances Act 2016 criminalizes production, supply, import, and export of ibogaine with maximum 7-year sentences, while personal possession remains technically lawful outside custodial settings
- Zero regulated, above-ground ibogaine treatment clinics operate in the UK; underground providers lack essential medical equipment (ECG monitoring, crash carts, trained emergency staff) and create safety risks
- MHRA approved one clinical trial (DemeRx Phase 1/2a at MAC Clinical Research Manchester in March 2021), demonstrating clinical trial pathway exists but is not a practical route for medical tourists
- UK residents travel to Portugal, Netherlands, or Mexico for ibogaine treatment due to complete absence of legal domestic options; foreign patients face considerable legal risks attempting to import ibogaine into the UK
Read the full United Kingdom report →
9 Poland PL 1.0/5 Poor Poland maintains an unambiguous criminal prohibition on ibogaine with no medical exemptions, research pathways, or compassionate-use provisions. Tabernanthe iboga is classified as Group I-N (most restricted narcotic) ... Full report
The evidence behind this score 5 cited points
- Tabernanthe iboga classified as Group I-N narcotic drug under Ministry of Health regulation Dz.U. 2024, poz. 1139 — the most restricted controlled substance category
- Possession of ibogaine punishable by up to 3 years imprisonment under Article 62 of the Act on Counteracting Drug Addiction; significant amounts carry 1-10 years
- No prescription, compassionate-use, or research authorization pathway exists for ibogaine in Poland, unlike medical cannabis (legal since 2018) or psilocybin (under clinical trials)
- Poland's leading private addiction clinic (Zeus Detox Rehab & SPA, Warsaw) explicitly confirms it does not provide ibogaine therapy and that the substance is 'not approved in Poland as a medication'
- Foreign patients are subject to the same criminal law as Polish citizens with no special immunity, visa category, or legal distinction for medical tourism purposes
Read the full Poland report →
10 Singapore SG 1.0/5 Poor Singapore maintains one of the world's most prohibitive legal frameworks for ibogaine, with explicit criminalization through both the generic tryptamine classification and the Psychoactive Substances framework (effect... Full report
The evidence behind this score 4 cited points
- Ibogaine is explicitly prohibited under the Psychoactive Substances framework (effective 1 June 2024) which criminalizes any substance capable of producing a psychoactive CNS effect
- Health Sciences Authority has not approved ibogaine for any therapeutic use; no licensed practitioner pathways or facility certification standards exist
- Section 8A of the Misuse of Drugs Act creates extraterritorial criminal liability for Singapore citizens/residents who consume controlled drugs abroad, with enforcement through hair follicle testing at Changi Airport detecting use within 3-6 months
- Central Narcotics Bureau operates zero-tolerance enforcement; criminal penalties include 1-10 years imprisonment, fines up to S$20,000 for consumption, and death penalty for trafficking above threshold quantities
Read the full Singapore report →
11 Turkey TR 1.0/5 Poor Turkey explicitly prohibits ibogaine under broad 'narcotic and psychotropic substances' legislation with no medical exception, research exemption, or compassionate use pathway. The government operates a zero-tolerance... Full report
The evidence behind this score 5 cited points
- Turkish Penal Code Articles 188–192 impose 10–30 year sentences for trafficking any 'narcotic and psychotropic substance' with no medical exception framework
- Turkey arrested 374,948 people on drug charges in 2024 under a zero-tolerance policy, operating an extremely aggressive enforcement environment
- No practitioner licensing, facility certification, or therapeutic exemption for ibogaine exists; TMMDA has not issued any approval and AMATEM-licensed addiction facilities do not offer ibogaine
- Moodist Hospital and NP Istanbul Brain Hospital—the hospitals marketed for ibogaine—offer only conventional addiction treatment (CBT, TMS, EMDR, pharmacotherapy) with no psychedelic component
- Importing ibogaine constitutes drug trafficking under Article 188 with 20–30 year penalty; Turkish customs actively intercepts contraband at airports
Read the full Turkey report →
12 Jordan JO 1.0/5 Poor Jordan maintains one of the most restrictive drug policy environments in the Middle East, with ibogaine de facto prohibited under the broad language of the 2021 Narcotic Drugs and Psychotropic Substances Law. The coun... Full report
The evidence behind this score 6 cited points
- Ibogaine covered under broad prohibition of 'narcotic and psychotropic substances' in 2021 Narcotic Drugs and Psychotropic Substances Law
- Zero ibogaine treatment facilities; JFDA has not registered any ibogaine-containing product as pharmaceutical
- Anti-Narcotics Department recorded 25,260 drug-related cases in 2024 following intensive enforcement crackdown initiated in 2022
- Criminal penalties: 2–25 years imprisonment for drug offenses, with death penalty applicable for trafficking linked to international criminal networks
- No gray market tolerance: no underground ibogaine clinics, no informal treatment networks, no history of selective non-enforcement toward medical providers
- Importing ibogaine for personal therapeutic use constitutes criminal violation subjecting foreign nationals to arrest, prosecution, and imprisonment
Read the full Jordan report →
13 Hungary HU 1.0/5 Poor Hungary presents one of Europe's most restrictive legal environments for ibogaine therapy. Ibogaine is explicitly classified as an illegal Schedule C substance (since January 2015) with "no therapeutic value," now con... Full report
The evidence behind this score 4 cited points
- Ibogaine listed under Schedule C of Government Regulation 66/2012 Annex 1 since January 2015, classified as having no therapeutic value [Why Was Ibogaine Banned in Hungary? - Drugreporter - January 2015]
- Constitution amended April 2025 to constitutionalize prohibition on drug production, use, distribution; ibogaine merged into main narcotics law June 2025 with escalated penalties [Hungary's 2025 Drug Laws: Stricter Rules, Rising Concerns - CMS Law - April 2025]
- Active enforcement with Operation Delta initiating 2,000+ criminal proceedings within two months; importation penalties now 2–8 years, distribution up to 20 years for aggravated cases [Tough Drug Law Shows Results - Hungary Today - 2025]
- No ibogaine treatment clinics, no medical authorization framework, no compassionate-use or research-exemption pathway; foreign patients face criminal liability for import or access [Drug Law in Hungary — Guide for Foreigners - Drugreporter/HCLU - 2023]
Read the full Hungary report →
14 Israel IL 1.0/5 Poor Ibogaine is explicitly prohibited in Israel under the Dangerous Drugs Ordinance (1973) with no medical exceptions. Criminal penalties reach 20 years imprisonment for supply and 3 years for possession. No licensed trea... Full report
The evidence behind this score 6 cited points
- Ibogaine classified as dangerous drug under Dangerous Drugs Ordinance (1973) with no therapeutic exemption
- Criminal penalties of up to 20 years for supply-related offences, 3 years for possession
- No licensed ibogaine treatment clinics operate in Israel as of June 2026
- Explicitly stated: no gray market or tolerated ibogaine treatment scene exists
- 2022 Ministry of Health notification permits only non-clinical research under Israeli Medical Cannabis Unit, not clinical patient treatment
- Medical tourists have zero legal access to ibogaine therapy; import of ibogaine constitutes illegal dangerous drug importation
Read the full Israel report →
15 India IN 1.0/5 Poor Ibogaine therapy is effectively illegal in India despite not being scheduled under the NDPS Act. The Drugs and Cosmetics Act 1940 prohibits clinical use of any drug lacking DCGI marketing authorization, and ibogaine h... Full report
The evidence behind this score 5 cited points
- Ibogaine has no DCGI marketing authorization under the Drugs and Cosmetics Act 1940, making clinical administration unlawful without IND approval
- Zero accredited hospitals or legal treatment clinics offer ibogaine therapy in India; no registered clinical trials exist
- Violators of drug approval law face prosecution, license revocation, and imprisonment; importing ibogaine without permission violates the Drugs and Cosmetics Act
- Foreign patients cannot obtain valid M-Visa documentation for ibogaine treatment as no recognized hospital will issue acceptance letters for unapproved drug therapy
- No government tolerance, gray-market operations, or semi-legal treatment centers exist; absence of enforcement reflects zero treatment activity, not official tolerance
Read the full India report →
16 United Arab Emirates AE 1.0/5 Poor The UAE maintains one of the world's most restrictive legal environments for ibogaine, with comprehensive prohibition under Federal Decree-Law No. 30 of 2021 and zero tolerance enforcement extending to metabolite dete... Full report
The evidence behind this score 5 cited points
- Ibogaine falls under broad psychotropic substance prohibition in Federal Decree-Law No. 30 of 2021 with no medical exemption issued
- Zero legal ibogaine clinics operate; no marketing authorization, compassionate use exemption, or research license exists
- UAE enforces zero-tolerance policy extending to trace metabolites, with mandatory prosecution and deportation for foreign nationals
- Cabinet Decision 43/2024 provides fines over detention but creates no medical treatment framework or pathway
- No documented gray market, tolerated providers, or government non-prosecution policy for ibogaine therapy
Read the full United Arab Emirates report →
17 Japan JP 1.0/5 Poor Japan maintains an explicit, actively enforced prohibition of ibogaine under the Narcotics and Psychotropics Control Act with no medical exemptions, compassionate use pathways, or gray-market tolerance. Possession car... Full report
The evidence behind this score 5 cited points
- Ibogaine is prohibited under the Narcotics and Psychotropics Control Act (1953/1990) with no approved medical use by PMDA
- Penalties for possession of controlled narcotics reach up to 7 years imprisonment with 99% conviction rate for drug offenses
- Foreign nationals face mandatory deportation plus minimum 5-year re-entry ban if caught with narcotics
- No licensed ibogaine treatment clinics exist; Medical Stay Visa explicitly excludes unauthorized narcotics and no import pathway exists for ibogaine
- Zero-tolerance enforcement with no documented gray-market providers or underground treatment centers operating
Read the full Japan report →
18 South Korea KR 1.0/5 Poor Ibogaine therapy is explicitly illegal in South Korea under the Narcotics Control Act, classified as a prohibited psychotropic substance with no legal pathways for medical use. The country enforces a zero-tolerance dr... Full report
The evidence behind this score 5 cited points
- Narcotics Control Act lists 478 prohibited substances including psychotropic substances and alkaloid derivatives covering tryptamines such as ibogaine
- No ibogaine treatment clinics operate in South Korea; foreign patients seeking therapy face criminal prosecution, substantial fines, and potential imprisonment
- Possession of psychotropic substances carries penalties of up to 10 years in prison or up to 100 million won under the Narcotics Control Act
- South Korea's 'no-drugs-abroad' law (2012) criminalizes citizens using drugs in foreign countries where legal; upon return, violations result in up to 5 years imprisonment
- Sophisticated Narcotics Information Management System (NIMS) ensures comprehensive monitoring; Korean Customs Office thoroughly inspects all substances at ports, airports, and in international mail
Read the full South Korea report →
19 Malaysia MY 1.0/5 Poor Malaysia maintains an explicitly prohibitory legal framework with ibogaine classified as a dangerous drug under the Dangerous Drugs Act 1952 with death penalty applicable for trafficking. No legal pathways exist for m... Full report
The evidence behind this score 6 cited points
- Ibogaine classified as Class A dangerous drug under Malaysia's Dangerous Drugs Act 1952 with death penalty applicable for trafficking
- No legal pathways: no medical exception framework, no compassionate use programme, no research exemption, no ministerial authorisation
- Active enforcement: 300,000+ drug-related arrests 2023–2025; 270 drug syndicates dismantled in 2025; 9 new drug-related death sentences in 2024
- No gray market tolerance: no ibogaine treatment clinics operate openly or in tolerated areas; Malaysia's enforcement environment makes any such operation untenable
- Foreign patients have no special status: identical exposure to Malaysian drug laws; no special medical visa categories for psychedelic therapy
- Government explicitly rejects policy reform: Ministry of Health stated in October 2024 it has no plans to amend the Dangerous Drugs Act to reduce penalties
Read the full Malaysia report →

See the full ranking, the 1–5 rubric and the reports →